Association of lipid profile with serum PON1 concentration in patients with chronic kidney disease

Figures & data

Table 1. Demographic characteristics of patients and controls.

	Controls	RF patients	HD patients
	(n = 30)	(n = 46)	(n = 44)
Age, years	57 ± 33	60 ± 20	68 ± 12
Sex (male/female)	14/16	26/20	24/20
BMI, kg/m^2	23.5 ± 1.0	24.0 ± 1.8	24.4 ± 1.1
Duration of HD, months	–	–	84 ± 113
Statin treatment (n %)	39	35	40
Creatinine, mg/dL	0.77 ± 0.18	2.05 ± 1.30a	9.24 ± 2.57^b^,^c
Urea, mg/dL	30 ± 8	76 ± 40^b	144 ± 35^b^,^c
Albumin, g/dL	4.56 ± 0.27	4.15 ± 0.36^b	4.13 ± 0.35^b

Notes: ^a p<0.01 versus controls.

^bp<0.001 versus controls.

^cp<0.001 versus RF patients.

Figure 1. Comparison of serum PON1 levels in RF and HD patients with or without (w/o) statin treatment.

Note: *p < 0.001 versus RF without statins and RF with statins, **p < 0.001 versus RF with statins.

Table 2. Lipid profile and PON1 concentration in patients and controls (C).

	Controls	RF patients	HD patients
	(n=30)	(n=46)	(n=44)
Total cholesterol, mg/dL	186 ± 25	182 ± 35	162 ± 34^Table Footnoteaa,Table Footnoteb
Triglycerides, mg/dL	78 ± 28	119 ± 58^Table Footnoteaa	138 ± 63^Table Footnoteaaa
LDL-C, mg/dL	100 ± 33	113 ± 34	85 ± 30^Table Footnotebb
HDL-C, mg/dL	69 ± 18	58 ± 16^Table Footnoteaa	43 ± 14^Table Footnoteaaa,Table Footnotebb
HDL2-C, mg/dL	36 ± 17	32 ± 12a	25 ± 11^Table Footnoteaa
HDL3-C, mg/dL	33 ± 5	26 ± 2^Table Footnoteaaa	18 ± 4^Table Footnoteaaa,Table Footnotebb
Apo A1, mg/dL	168 ± 25	147 ± 24^a	138 ± 40^Table Footnoteaaa
Apo B, mg/dL	82 ± 22	97 ± 27	78 ± 27^Table Footnoteb
PON1, μg/mL	53.42 ± 12.50	46.30 ± 19.55	25.94 ± 12.79^Table Footnoteaaa,Table Footnotebb

Notes: ^a p<0.05 versus C.

^aap<0.01 versus C.

^aaap<0.001 versus C.

^bp<0.05 versus RF.

^bbp<0.001 versus RF.

Table 3. Lipid profile and PON1 concentration in CKD patients without (w/o) and with statins.

	RF patients		HD patients
	W/o statins	With statins	W/o statins	With statins
	(n=30)	(n=16)	(n=26)	(n=18)
Cholesterol, mg/dL	190 ± 38	174 ± 32	164 ± 32^Table Footnotea	160 ± 20^Table Footnotea
Triglycerides, mg/dL	125 ± 55	113 ± 33	140 ± 72	136 ± 28
LDL-C, mg/dL	118 ± 34	107 ± 30	84 ± 26^Table Footnoteaa	86 ± 19^Table Footnotea
HDL-C, mg/dL	55 ± 18	62 ± 15	44 ± 15^b	42 ± 4^b
HDL2-C, mg/dL	30 ± 12	33 ± 13	29 ± 15	21 ± 7
HDL3-C, mg/dL	22 ± 3	28 ± 3^Table Footnoteaa	14 ± 2^Table Footnoteaa,Table Footnotebb	20 ± 3^Table Footnotebb,Table Footnotec
Apo A1, mg/dL	138 ± 22	159 ± 26	135 ± 27^b	140 ± 52^b
Apo B, mg/dL	101 ± 26	89 ± 26	75 ± 21^a	80 ± 21
PON1, μg/mL	39.48 ± 9.62	49.31 ± 14.94	24.22 ± 12.44^Table Footnoteaa,Table Footnotebb	30.42 ± 12.62^Table Footnotebb

Notes: ^ap<0.05 versus RF without statins.

^aap<0.001 versus RF without statins.

^bp<0.05 versus RF with statins.

^bbp<0.001 versus RF with statins.

^cp<0.001 HD without statins.

Table 4. Linear regression analysis between serum PON1 concentration, lipids and apolipoproteins in CKD patients.

	RRF patients (n=46)		HD patients (n=44)
	r	p	r	p
Cholesterol	−0.167	0.377	−0.205	0.259
Triglycerides	−0.107	0.612	−0.121	0.531
LDL-C	−0.213	0.266	−0.423	0.014
HDL-C	0.462	0.040	0.471	0.013
HDL2-C	0.122	0.536	0.219	0.220
HDL3-C	0.480	0.032	0.490	0.010
Apo A1	0.468	0.028	0.399	0.032
Apo B	−0.166	0.389	−0.205	0.269

Table 5. Multiple regression analysis of lipid-associated factors influencing serum PON1 concentration of CKD patients.

	RF patients (n = 46)		HD patients (n = 44)
Independent variable	β	p	β	p
HDL-C	0.115	0.699	0.360	0.604
HDL3-C	0.332	0.010	0.236	0.812
Apo-A1	0.298	0.026	0.384	0.158
LDL-C	−0.105	0.277	−0.331	0.026
Statins	0.052	0.268	0.344	0.020

Notes: R² = 0.395, F = 2.746, p = 0.046 for RF model. R² = 0.503, F = 3.447, p = 0.025 for HD model.